NEKTAR THERAPEUTICS — Director's Dealing 2021

Oct 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2021-10-12

Reporting Person: Labrucherie Gil M (SVP, COO & CFO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-12	Stock Option	$21.79	A	71550	Acquired	2027-12-11	Common Stock (71550)	Direct

Footnotes

F1: These stock options were granted on December 12, 2019 under the Company's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements.

F2: The Organization and Compensation Committee of the Board of Directors of the Company determined that the performance-based vesting requirement for these stock options was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these stock options vested on the next monthly vesting date (October 12, 2021) following the date that the performance-based vesting requirement was satisfied.

F3: These stock options vest on a monthly pro-rata basis over a period of four years from the grant date (December 12, 2019).